China Medical System(867.HK) Was Selected as the “Most Popular Southbound Stock Connect Company” of 2023 Annual Golden GuruClub Awards

Company News

On December 21, 2023, at the award ceremony of the “8th Global Investment Carnival” hosted by GuruClub, China Medical System (867.HK) stood out among over a hundred Hong Kong-listed companies with its sound business performance, outstanding innovation achievements and solid returns for shareholders, winning the award of ” Most Popular Southbound Stock Connect Company”, continuously enhancing its reputation in the capital market.


The “Golden GuruClub Awards” annual outstanding company selection by GuruClub is one of the most influential rankings in the capital market. The ” Most Popular Southbound Stock Connect Company” award aims to commend listed companies with health corporate governance, leading industry position, promising business structure, and ability to provide sustainable and solid value returns for investors. Wining this award represents the capital market’s recognition of CMS’s outstanding performance this year.


Since its listing on the main board of the Hong Kong Stock Exchange in 2010, CMS has been adhered to compliant operation and innovation development under  continuously improved governance system. The company has maintained steady performance growth over years, with its annual compound growth rate in the past 15 years of sales revenue (in the case that all medicines were directly sold by the Group) and net profit exceeding 20%, maintaining a ROE of over 20% and 40% of net profit as dividends, providing investors with sustainable and solid value returns.


After over five years of innovation investment and R&D advancement, CMS has continuously delivered innovation outcomes. In 2023, 3 of CMS’ innovative products were successfully approved for marketing in China, 2 innovative products are under NDA review in China, and more than 10 innovative products are steadily advancing China registration clinical trials with RCTs mainly. So far this year, CMS has had a total of 5 drugs been included or continued to be included in the National Reimbursement Drug List, which will further improve the accessibility and affordability of these high-quality drugs, benefiting more domestic patients.


Staying with the original aspiration and founding mission in mind, CMS will actively fulfill its mission of “providing competitive products and services to meet unmet medical needs” and continue to provide innovative pharmaceutical products with differentiated clinical value for patients, while maintaining effective communication with investors to actively convey corporate value and create greater returns for shareholders.